Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1

US8569292B2 · kind B2 · utility

Assignees

• Vitae Pharmaceuticals, LLC · US
• Boehringer Ingelheim International GmbH · DE

Inventors

• David A. Claremon · Audubon, US
• Linghang Zhuang · Doylestown, US
• Katerina Leftheris · Skillman, US
• Colin M. Tice · Ambler, US
• Zhenrong Xu · Forest Park, US
• Yuanjie Ye · Ambler, US
• Suresh B. Singh · Kendall Park, US
• Salvacion Cacatian · Conshohocken, US
• Frank Himmelsbach · Mittelbiberach, DE
• Matthias Eckhardt · Hannover, DE
• Wei Zhao · North Potomac, US

Key dates

• Filing date: Apr 30, 2009
• Grant date: Oct 29, 2013
• Expiry date: Jun 2, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to novel compounds of the Formula I, Ik, Iq1-21, Ir1-21, Is1-21, It1-7, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.